Publications
Detailed Information
High-dose cyclophosphamide-mediated anti-tumor effects by the superior expansion of CD44(high) cells after their selective depletion
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, So-Hee | - |
dc.contributor.author | Yoon, Il-Hee | - |
dc.contributor.author | Kim, Yong-Hee | - |
dc.contributor.author | Yang, Seung Ha | - |
dc.contributor.author | Nam, Hye-Young | - |
dc.contributor.author | Kim, Youngji | - |
dc.contributor.author | Park, Chung-Gyu | - |
dc.contributor.author | Park, Chan-Sik | - |
dc.contributor.author | Kim, Bongi | - |
dc.contributor.author | Park, Min-Jung | - |
dc.date.accessioned | 2012-06-11T01:50:09Z | - |
dc.date.available | 2012-06-11T01:50:09Z | - |
dc.date.issued | 2010-03 | - |
dc.identifier.citation | IMMUNOBIOLOGY; Vol.215 3; 182-193 | ko_KR |
dc.identifier.issn | 0171-2985 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76935 | - |
dc.description.abstract | As alkylating agents, cyclophosphamides (CTX) are used to treat various cancers and, ironically, to boost immune responses. In the present study, we attempted to elucidate the mechanism responsible for the immunomodulatory effect of high-dose CTX in an established tumor model. A single injection of high-dose CTX increased the survival rate of immunocompetent, but not immunodeficient, mice. Notably, 10 days after CTX injection, the number of CD44(high) memory T cells significantly increased, without a selective decrease in the actual number and percentage of CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs). However, the proportion of Tregs among CD4(+) T cells decreased due to expansion of memory and other CD4+ T cell subtypes. This outcome was accompanied by an increase in IL-15 mRNA and up-regulation of IL-15 receptors in the CD44(+)CD8(+) T cell compartment. We postulate that the CTX-induced change in T cell balance may increase anti-tumor immunity. (C) 2009 Elsevier GmbH. All rights reserved. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | ELSEVIER GMBH, URBAN & FISCHER VERLAG | ko_KR |
dc.subject | Anti-tumor effects | ko_KR |
dc.subject | Regulatory T cell | ko_KR |
dc.subject | Memory T cell | ko_KR |
dc.subject | IL-15/IL-15R | ko_KR |
dc.subject | Cyclophosphamide | ko_KR |
dc.title | High-dose cyclophosphamide-mediated anti-tumor effects by the superior expansion of CD44(high) cells after their selective depletion | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 홍소희 | - |
dc.contributor.AlternativeAuthor | 윤일희 | - |
dc.contributor.AlternativeAuthor | 김용희 | - |
dc.contributor.AlternativeAuthor | 양승하 | - |
dc.contributor.AlternativeAuthor | 박민정 | - |
dc.contributor.AlternativeAuthor | 남혜영 | - |
dc.contributor.AlternativeAuthor | 김봉이 | - |
dc.contributor.AlternativeAuthor | 김영지 | - |
dc.contributor.AlternativeAuthor | 박찬식 | - |
dc.contributor.AlternativeAuthor | 박정규 | - |
dc.identifier.doi | 10.1016/j.imbio.2009.01.010 | - |
dc.citation.journaltitle | IMMUNOBIOLOGY | - |
dc.description.citedreference | SHEVACH EM, 2008, J CLIN IMMUNOL | - |
dc.description.citedreference | Ghiringhelli F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI 10.1007/s00262-006-0225-8 | - |
dc.description.citedreference | Bracci L, 2007, CLIN CANCER RES, V13, P644, DOI 10.1158/1078-0432.CCR-06-1209 | - |
dc.description.citedreference | Brode S, 2006, J IMMUNOL, V177, P6603 | - |
dc.description.citedreference | Motoyoshi Y, 2006, ONCOL REP, V16, P141 | - |
dc.description.citedreference | Taieb J, 2006, J IMMUNOL, V176, P2722 | - |
dc.description.citedreference | Teague RM, 2006, NAT MED, V12, P335, DOI 10.1038/nm1359 | - |
dc.description.citedreference | WANG YE, 2006, GENOME INFORM, V17, P23 | - |
dc.description.citedreference | de Jonge ME, 2005, THER DRUG MONIT, V27, P756 | - |
dc.description.citedreference | Ikezawa Y, 2005, J DERMATOL SCI, V39, P105, DOI 10.1016/j.jdermsci.2005.02.002 | - |
dc.description.citedreference | Klebanoff CA, 2005, P NATL ACAD SCI USA, V102, P9571, DOI 10.1073/pnas.0503726102 | - |
dc.description.citedreference | Lutsiak MEC, 2005, BLOOD, V105, P2862 | - |
dc.description.citedreference | Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982 | - |
dc.description.citedreference | Viguier M, 2004, J IMMUNOL, V173, P1444 | - |
dc.description.citedreference | Ghiringhelli F, 2004, EUR J IMMUNOL, V34, P336 | - |
dc.description.citedreference | Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122 | - |
dc.description.citedreference | Matar P, 2002, CANCER IMMUNOL IMMUN, V50, P588, DOI 10.1007/s00262-001-0237-3 | - |
dc.description.citedreference | Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784 | - |
dc.description.citedreference | Schiavoni G, 2000, BLOOD, V95, P2024 | - |
dc.description.citedreference | ANDRADEMENA CE, 1994, INT J TISSUE REACT, V16, P95 | - |
dc.description.citedreference | HOOVER SK, 1990, CANCER IMMUNOL IMMUN, V31, P121 | - |
dc.description.citedreference | BERD D, 1982, CANCER RES, V42, P4862 | - |
dc.description.tc | 2 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.